<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586634</url>
  </required_header>
  <id_info>
    <org_study_id>CP327</org_study_id>
    <nct_id>NCT04586634</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial on Transanal Irrigation</brief_title>
  <official_title>Randomized Clinical Trial Assessing the Effect of Transanal Irrigation With Cone Catheter Versus Conservative Bowel Management on Symptoms of Low Anterior Resection Syndrome After Rectal Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective The primary objective is to demonstrate superiority of the Peristeen cone catheter&#xD;
      compared to standard of care.&#xD;
&#xD;
      The secondary objective is to investigate quality of life and different benefits and aspects&#xD;
      of treatment and satisfaction with the Peristeen cone catheter.&#xD;
&#xD;
      Design of the investigation This is a randomised, open-label, parallel investigation&#xD;
      comparing the Peristeen cone catheter with standard of care in subjects with major LARS (LARS&#xD;
      score ≥ 30). Each subject will be enrolled for a study duration of 12 weeks. Subjects will be&#xD;
      randomized to the treatments stratified by neo-adjuvant radiotherapy.&#xD;
&#xD;
      The comparator in this study will be current standard of care for patients with LARS which is&#xD;
      conservative bowel management. This is defined as: Supportive therapy according to the&#xD;
      individual treatment protocols available at each participating site.&#xD;
&#xD;
      Primary endpoint and secondary endpoints&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      • LARS score, obtained from the LARS score questionnaire*&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Number of subjects with Major LARS*&#xD;
&#xD;
        -  FIQL Score - scale 1, Modified American Society for Colorectal Surgeons Questionnaire*&#xD;
&#xD;
        -  FIQL Score - scale 2, Modified American Society for Colorectal Surgeons Questionnaire*&#xD;
&#xD;
        -  FIQL Score - scale 3, Modified American Society for Colorectal Surgeons Questionnaire*&#xD;
&#xD;
        -  FIQL Score - scale 4, Modified American Society for Colorectal Surgeons Questionnaire*&#xD;
&#xD;
        -  EQ-5D-5L - utility score*&#xD;
&#xD;
        -  EQ-5D-5L - VAS score (scale 0-10 cm)*&#xD;
&#xD;
        -  Satisfaction with treatment (scale 0-10 cm)*&#xD;
&#xD;
        -  Number of adverse events* *All endpoints are measured per subject at study termination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LARS score</measure>
    <time_frame>measured pr subject at study termination after 12 weeks</time_frame>
    <description>obtained from the LARS score questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Low Anterior Resection Syndrome</condition>
  <arm_group>
    <arm_group_label>Peristeen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects to use newly developed Peristeen cone catherter device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>subjects continue with their standard of care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peristeen cone catheter</intervention_name>
    <description>The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.</description>
    <arm_group_label>Peristeen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be at least 18 years of age and have full legal Capacity&#xD;
&#xD;
          2. Have given written informed consent&#xD;
&#xD;
          3. Be mental and physical capable to perform transanal irrigation with cone catheter&#xD;
&#xD;
          4. Have a LARS score ≥ 30 after rectal resection&#xD;
&#xD;
          5. Be treated according to individual treatment protocol for conservatory bowel&#xD;
             management at participating site&#xD;
&#xD;
          6. Have proof of complete healing of the anastomosis by endoscopy or radiology before&#xD;
             stoma closure&#xD;
&#xD;
          7. At least 3-months from last surgery in colorectum&#xD;
&#xD;
          8. Be evaluated to be suitable for transanal Irrigation procedure with a cone catheter by&#xD;
             endoscopy, defecography or comparable procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active/recurrent colorectal cancer&#xD;
&#xD;
          2. Leaking anastomosis&#xD;
&#xD;
          3. Known anal or colorectal stenosis&#xD;
&#xD;
          4. Within 4 weeks of endoscopic polypectomy&#xD;
&#xD;
          5. Ischaemic colitis&#xD;
&#xD;
          6. Acute inflammatory bowel disease&#xD;
&#xD;
          7. Acute diverticulitis&#xD;
&#xD;
          8. Current or planned pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Meurette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lone Pedersen, PhD</last_name>
    <phone>+4549113259</phone>
    <email>dklgjp@coloplast.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas W. Hansen</last_name>
    <phone>+4549111187</phone>
    <email>dkandwh@coloplast.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Coloplast A/S</name>
      <address>
        <city>Humlebæk</city>
        <zip>3050</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

